Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 22,184 Shares of Stock

Posted by Andrew Walz on May 21st, 2026

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) Director Luke Evnin sold 22,184 shares of the company’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $0.50, for a total transaction of $11,092.00. Following the transaction, the director directly owned 1,104,312 shares of the company’s stock, valued at approximately $552,156. This represents a 1.97% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

On Wednesday, May 20th, Luke Evnin sold 85,895 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.43, for a total transaction of $36,934.85.
On Tuesday, May 19th, Luke Evnin sold 62,970 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $28,336.50.
On Tuesday, May 12th, Luke Evnin sold 67,885 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total transaction of $43,446.40.
On Monday, May 11th, Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total transaction of $22,745.16.
On Friday, May 8th, Luke Evnin sold 305,741 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.70, for a total transaction of $214,018.70.
On Thursday, May 7th, Luke Evnin sold 79,086 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total value of $49,824.18.
On Wednesday, May 6th, Luke Evnin sold 14,635 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.66, for a total value of $9,659.10.
On Tuesday, May 5th, Luke Evnin sold 6,860 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.69, for a total value of $4,733.40.
On Monday, May 4th, Luke Evnin sold 47,963 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.72, for a total value of $34,533.36.
On Friday, May 1st, Luke Evnin sold 58,394 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.73, for a total value of $42,627.62.

Werewolf Therapeutics Price Performance

Werewolf Therapeutics stock opened at $0.44 on Thursday. The stock’s 50-day moving average is $0.79 and its 200-day moving average is $0.79. The company has a market cap of $21.29 million, a price-to-earnings ratio of -0.35 and a beta of 0.41. Werewolf Therapeutics, Inc. has a 12 month low of $0.40 and a 12 month high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.04. Research analysts anticipate that Werewolf Therapeutics, Inc. will post -1.29 EPS for the current year.

Wall Street Analyst Weigh In

HOWL has been the subject of a number of research reports. Wall Street Zen cut Werewolf Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Monday, April 20th. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Werewolf Therapeutics presently has an average rating of “Hold” and a consensus target price of $3.75.

Check Out Our Latest Report on Werewolf Therapeutics

Hedge Funds Weigh In On Werewolf Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Regal Investment Advisors LLC boosted its holdings in Werewolf Therapeutics by 93.3% in the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after acquiring an additional 25,389 shares during the period. Vontobel Holding Ltd. boosted its holdings in Werewolf Therapeutics by 66.7% in the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after acquiring an additional 24,003 shares during the period. Qube Research & Technologies Ltd purchased a new position in Werewolf Therapeutics in the 2nd quarter worth approximately $48,000. AQR Capital Management LLC purchased a new position in Werewolf Therapeutics in the 1st quarter worth approximately $79,000. Finally, Bridgeway Capital Management LLC boosted its holdings in Werewolf Therapeutics by 157.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after acquiring an additional 62,414 shares during the period. Hedge funds and other institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

(Get Free Report)

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.